abs351.txt	combination	immunotherapy	has	recently	emerged	as	a	powerful	cancer	treatmentstrategy		promising	treatment	approach	utilizes	coadministration	ofantagonistic	antibodies	to	block	checkpoint	inhibitor	receptors	such	asantiprogrammed	cell	death-1	(apd1)	alongside	agonistic	activatecostimulatory	antitumor	necrosis	factor	receptor	superfamilymember	4	(aox40)	optimal	t-cell	activation	is	achieved	when	bothimmunomodulatory	agents	simultaneously	engage	t-cells	and	promote	synergisticproactivation	signaling	however	standard	administration	of	these	therapeuticsas	free	results	in	suboptimal	binding	events	with	only	asubset	the	both	apd1	aox40	here	it	shown	thatprecise	spatiotemporal	codelivery	using	nanoparticles	(np)(dual	dinp)	improved	enhanced	therapeutic	efficacy	increased	immunological	memory	isdemonstrated	that	dinp	elicits	higher	rates	vitro	thanfree	importantly	demonstrated	two	tumor	models	thatcombination	administered	form	more	effective	thanthe	same	regimen	this	work	demonstrates	novelstrategy	improve	nanotechnology
